Your vision blurs, and reading even your favorite book seems impossible. You can no longer recognize the face of a loved one. And driving at night frightens you because of the blurry view ahead. These frustrations are what millions of people with macular degeneration live with every day.
You feel dependent on others for simple tasks. Depression and anxiety creep in as you worry about your future. Almost a third of AMD patients develop depression because vision loss impacts every part of daily life. The worst part is that macular degeneration causes no pain, so you may not know you have it until your vision already suffers.
But here’s the good news: a spate of new drugs in 2024 and 2025 finally offers you real hope. You now have choices for treatments that can slow disease progression and help you hold onto more of your sight. These game changing medications target both the dry and wet forms of the disease, offering solutions that didn’t exist just a few short years ago.
What is Macular Degeneration?
Macular degeneration is a disease that may affect the small area in your retina responsible for your central vision and fine detail, called the macula. This generally comes in two forms: dry and wet.
Dry macular degeneration, also called geographic atrophy, causes slow vision loss over time. Wet macular degeneration involves abnormal blood vessels that leak fluid, leading to rapid vision loss.
Breakthrough Drugs for Dry AMD
Medical research has recently delivered new FDA-approved new treatments for dry macular degeneration, giving patients real options to slow the disease.
-
Pegcetacoplan (Syfovre)
In February 2023, the FDA approved pegcetacoplan. It’s the first treatment ever for geographic atrophy. This medication blocks complement proteins in your immune system that damage your retinal cells. You get it via eye injections once a month or every other month.
Clinical trials demonstrated that pegcetacoplan, dosed every month, reduced GA lesion growth by 22%. The medicine slows the progression of the disease but does not restore lost vision.
-
Avacincaptad Pegol (Izervay)
In August 2023, the FDA approved avacincaptad as the second treatment for GA. This drug also acts upon the complement proteins, but at a different part of the immune system. It is given as a monthly injection into the eye.
Studies found avacincaptad reduced GA expansion by 27% in one trial and 14% in another over 12 months. A 2024 analysis showed pegcetacoplan performed 30.4% better than avacincaptad in slowing lesion growth.
Revolutionary Treatments for Wet AMD
Researchers are also developing new treatments for wet macular degeneration that aim to reduce abnormal blood vessel growth in the eye.
-
Gene Therapy SAR402663
It is a one-time gene therapy, SAR402663, developed by Sanofi, which received FDA Fast Track designation in September 2025. The treatment delivers genetic material into your eye that tells cells to make proteins blocking abnormal blood vessel growth.
The treatment is designed to avoid the frequent eye injections that wet AMD patients currently undergo. During the phase 1/2 clinical trials, the researchers are testing SAR402663 on about 66 patients. Results will yield whether one shot provides long-lasting benefits.
-
Susvimo Port Delivery System
Susvimo is the first implantable drug delivery system for wet AMD. The device sits in your eye, continuously releasing ranibizumab, a proven anti-VEGF medication. Patients need only two refills per year instead of monthly injections.
Clinical trials have shown that Susvimo maintains vision gains equal to monthly shots of ranibizumab. Five-year data, presented in 2025, confirmed that the implant continues to work long-term with biannual refills.
-
EYLEA HD (Aflibercept 8 mg)
Regeneron received FDA approval in November 2025 for EYLEA HD to treat retinal vein occlusion, which causes eye problems similar to those of wet AMD. The higher-dose formula extends the treatment interval to every 8 weeks after the initial monthly doses. This medication is also effective for wet AMD and halves the injection frequency versus standard treatments.
-
Vabysmo (Faricimab)
Vabysmo acts on two pathways that disturb blood vessels: VEGF-A and angiopoietin-2. This dual activity brings about better disease control with extended dosing intervals. Four-year data from 2025 showed almost 80% of patients maintained extended dosing schedules. More than 60% of patients with difficult-to-treat wet AMD showed no damaging lesions.
-
PRIMA System: A Vision Implant
The PRIMA System offers hope for people with advanced dry AMD who have lost central vision. This revolutionary implant works with special glasses that convert light into signals your healthy retinal cells can understand.
European trials with 43 patients showed 84.4% regained the ability to read letters, numbers, and words. On average, patients read up to five lines on an eye chart after receiving the implant. The device awaits approval for use in the UK and other countries.
How do These Drugs Work?
Most new drugs for wet AMD block VEGF, a protein that causes abnormal blood vessel growth. Anti-VEGF medications shrink leaky vessels and help your body absorb fluid under the retina. Some newer drugs target multiple pathways simultaneously for better results.
Dry AMD treatments work differently by blocking complement proteins that trigger inflammation and cell death. These drugs slow the spread of damaged areas in your retina.
Gene therapy represents the newest approach, teaching your eye cells to make their own anti-VEGF proteins. This method could provide years of treatment from a single injection.
Treatment Frequency and Convenience
Traditional wet AMD treatments require monthly eye injections for years. New options reduce this burden significantly. Susvimo needs refills only twice yearly. Vabysmo allows extended dosing for most patients. EYLEA HD reduces injection frequency to 8-week intervals.
Dry AMD treatments currently require monthly or every-other-month injections. The PRIMA implant needs a one-time surgical procedure. Gene therapy aims for a single-dose treatment lasting years.
What Does This Mean for Patients?
These advances give you more choices than ever before. You can work with your eye doctor to choose treatments that fit your lifestyle and disease stage. Fewer injections mean less time at the clinic and lower treatment burden.
After decades of no treatment, dry AMD patients finally have FDA-approved options. While these drugs may slow progression rather than restore vision, early treatment can preserve more of your sight.
Wet AMD patients benefit from longer-lasting treatments and implants that eliminate frequent injections. People with advanced vision loss may consider the PRIMA implant to regain reading ability.
Take Control of Your Vision Today
Your eyes are worth expert care. The longer you wait, the worse your vision will become. The latest treatments work best if started early, empowering you to take charge of protecting your vision and preserving your independence.
Schedule your comprehensive eye examination with RVAF today. Our specialists will assess your eye health, discuss the latest treatment options, and create a personalized care plan tailored to your needs. Whatever your needs, from preventive care to advanced treatment, we guide you every step of the way.
In addition, you can book your appointment online to compare macular degeneration vs glaucoma. Your clearer tomorrow starts with a straightforward step today.
Frequently Asked Questions
1. What is the FDA-approved new drug for macular degeneration?
The drug Pegcetacoplan became FDA-approved in February 2023 as the first treatment for geographic atrophy (dry macular degeneration). According to a study from 2024, it proved superior to avacincaptad pegol in reducing lesion growth rate by more than 30%.
2. Is there a one-time treatment for macular degeneration?
Another potential treatment for geographic atrophy is SAR402663, a single administration gene therapy made by Sanofi company. In September 2025, it got FDA Fast Track status, and now the therapy is tested during Phase 1/2 clinical trials.
3. What is the latest drug for wet macular degeneration?
Faricimab (Vabysmo) is a new FDA-approved drug which blocks both VEGF and angiopoietin-2 and requires only 3 to 4 months to be administered next time. Also, there is Susvimo, an implantable drug delivery system for treating wet AMD.
4. Are there new treatment options for dry macular degeneration?
Yes. The newly approved treatments for geographic atrophy (an advanced form of dry AMD) are able to slow down disease development and preserve vision.